

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 609 476 A8

(12)

CORRECTED EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1)
INID code(s) 71

(51) Int Cl.:

A61K 35/78 ^(1985.01) **A61P 1/16** ^(2000.01)
A61P 31/12 ^(2000.01) **A61P 35/00** ^(2000.01)

(48) Corrigendum issued on:

12.04.2006 Bulletin 2006/15

(86) International application number:

PCT/JP2004/002706

(43) Date of publication:

28.12.2005 Bulletin 2005/52

(87) International publication number:

WO 2004/078191 (16.09.2004 Gazette 2004/38)

(21) Application number: **04717266.3**

(22) Date of filing: **04.03.2004**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

• **KANEKO, Shuichi,**
Kanazawa University Hospital
Kanazawa-shi,
Ishikawa 9208641 (JP)

(30) Priority: **05.03.2003 JP 2003059056**

(71) Applicant: **Original Image Co., Ltd.**

Yokohama-shi
Kanagawa 231-0004 (JP)

(74) Representative: **HOFFMANN EITLE**

Patent- und Rechtsanwälte
Arabellastrasse 4
D-81925 München (DE)

(72) Inventors:

• **YOSHIDA, Satoshi**
Itabashi-ku, Tokyo 175-0082 (JP)

(54) **COMPOSITION FOR TREATING HEPATITIS C**

(57) By administering a composition comprising pumpkin seed, safflower, plantain and honeysuckle, subjective symptoms (for example, general malaise and abdominal swelling) of a patient with chronic hepatitis C can be eliminated and, moreover, objective symptoms diagnosed by a medical doctor (for example, liver enlargement and palm erythema) can be relieved or eliminated. From 1 to 3 months after the administration of the com-

position, a significant decrease in hepatitis C virus RNA level is gradually observed. Therefore, the above composition is useful at least as a composition for treating chronic hepatitis C. In particular, it is advantageous in treating a chronic hepatitis C patient showing a high chronic hepatitis C virus RNA level.

EP 1 609 476 A8